公司資料
Day One Biopharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- DAWN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
21.53 USD (+0.19%)
收盤價
最後更新: 2026年4月22日
2.22B USD
市值
股價為何變動
Current closing-price context is not available for DAWN.
公司概覽
Pediatric and Rare Oncology
Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types.
OJEMDA
OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an activating RAF alteration. It provides Day One’s commercial foundation and is being studied in the frontline setting.
FIREFLY Program
FIREFLY-1 supported approval and continues to provide long-term durability data. FIREFLY-2 is a pivotal Phase 3 trial evaluating OJEMDA in newly diagnosed pediatric low-grade glioma.
Emi-Le
Emi-Le is a B7-H4-directed antibody-drug conjugate acquired with Mersana Therapeutics. It is in Phase 1 development for adenoid cystic carcinoma and broadens Day One into rare adult cancers.
DAY301
DAY301 is a PTK7-targeted antibody-drug conjugate in Phase 1a dose escalation. The program adds a second ADC mechanism and another opportunity beyond the OJEMDA franchise.
未來催化劑
- Completion of enrollment in the Phase 3 FIREFLY-2 trial expected in the first half of 2026.
- Updated Phase 1 Emi-Le data expected in mid-2026.
- Initial Phase 1a DAY301 data and program update expected in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。